North America Motion Sickness Treatment Market Size, Share & Industry Trends Analysis Report By Drug Class (Antihistamines, Anticholinergics and Others), By Route of Administration, By Distribution Channel, By Country and Growth Forecast, 2023 - 2029
The North America Motion Sickness Treatment Market would witness market growth of 2.5% CAGR during the forecast period (2023-2029).
The market's growth is anticipated to be propelled by untapped, emerging markets with high potential, owing to the presence of enhanced healthcare infrastructure, rising unmet healthcare demands, and a surge in need for efficient motion sickness medication.
Furthermore, certain demographics may be more susceptible to motion sickness symptoms, such as expectant mothers and individuals between the ages of 2 and 12. The initial indications of motion sickness encompass queasiness, heightened salivation, burping, perspiration, hyperventilation, and a general sense of discomfort. Motion sickness can be prevented or treated through pharmacological therapies such as anticholinergic drugs, antihistaminic drugs, and various other medications.
The North American over-the-counter drugs sector is experiencing growth due to the rising trend of individuals choosing OTC drugs for minor complications instead of seeking intensive treatment from healthcare professionals. This trend is particularly prevalent in countries such as the U.S., Canada, and Mexico. Furthermore, the emergence of numerous mid-size and small players in the region has led to the introduction of innovative medications at reduced prices, thereby enhancing the over-the-counter drugs sector in the region. The wider usage of OTC, like antihistamines, by general consumers for various minor health issues like motion sickness is expected to propel the motion sickness treatment market growth in the region.
The US market dominated the North America Motion Sickness Treatment Market by Country in 2022; thereby, achieving a market value of $131.6 Million by 2029. The Canada market is poised to grow at a CAGR of 4.5% during (2023 - 2029). Additionally, The Mexico market would witness a CAGR of 4.3% during (2023 - 2029).
Based on Drug Class, the market is segmented into Antihistamines, Anticholinergics and Others. Based on Route of Administration, the market is segmented into Oral and Others. Based on Distribution Channel, the market is segmented into Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Viatris, Inc., Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals, Inc., Baxter International, Inc., Novartis AG, Abbott Laboratories, Sun Pharmaceutical Industries Ltd., Zydus Lifesciences Ltd., Prestige Consumer Healthcare, Inc., WellSpring Pharmaceutical Corporation (Avista Capital Partners).
Scope of the Study
Market Segments covered in the Report:
By Drug Class
Antihistamines
Anticholinergics
Others
By Route of Administration
Oral
Others
By Distribution Channel
Drug Store & Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
By Country
US
Canada
Mexico
Rest of North America
Companies Profiled
Viatris, Inc.
Teva Pharmaceutical Industries Ltd.
Amneal Pharmaceuticals, Inc.
Baxter International, Inc.
Novartis AG
Abbott Laboratories
Sun Pharmaceutical Industries Ltd.
Zydus Lifesciences Ltd.
Prestige Consumer Healthcare, Inc.
WellSpring Pharmaceutical Corporation (Avista Capital Partners)
Unique Offerings from KBV Research
Exhaustive coverage
Highest number of market tables and figures
Subscription based model available
Guaranteed best price
Assured post sales research support with 10% customization free
- Chapter 1. Market Scope & Methodology
- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
- 1.4.1 North America Motion Sickness Treatment Market, by Drug Class
- 1.4.2 North America Motion Sickness Treatment Market, by Route of Administration
- 1.4.3 North America Motion Sickness Treatment Market, by Distribution Channel
- 1.4.4 North America Motion Sickness Treatment Market, by Country
- 1.5 Methodology for the research
- Chapter 2. Market Overview
- 2.1 Introduction
- 2.1.1 Overview
- 2.1.1.1 Market composition & scenario
- 2.2 Key Factors Impacting the Market
- 2.2.1 Market Drivers
- 2.2.2 Market Restraints
- Chapter 3. North America Motion Sickness Treatment Market by Drug Class
- 3.1 North America Antihistamines Market by Country
- 3.2 North America Anticholinergics Market by Country
- 3.3 North America Others Market by Country
- Chapter 4. North America Motion Sickness Treatment Market by Route of Administration
- 4.1 North America Oral Market by Country
- 4.2 North America Others Market by Country
- Chapter 5. North America Motion Sickness Treatment Market by Distribution Channel
- 5.1 North America Drug Store & Retail Pharmacies Market by Country
- 5.2 North America Hospital Pharmacies Market by Country
- 5.3 North America Online Pharmacies Market by Country
- Chapter 6. North America Motion Sickness Treatment Market by Country
- 6.1 US Motion Sickness Treatment Market
- 6.1.1 US Motion Sickness Treatment Market by Drug Class
- 6.1.2 US Motion Sickness Treatment Market by Route of Administration
- 6.1.3 US Motion Sickness Treatment Market by Distribution Channel
- 6.2 Canada Motion Sickness Treatment Market
- 6.2.1 Canada Motion Sickness Treatment Market by Drug Class
- 6.2.2 Canada Motion Sickness Treatment Market by Route of Administration
- 6.2.3 Canada Motion Sickness Treatment Market by Distribution Channel
- 6.3 Mexico Motion Sickness Treatment Market
- 6.3.1 Mexico Motion Sickness Treatment Market by Drug Class
- 6.3.2 Mexico Motion Sickness Treatment Market by Route of Administration
- 6.3.3 Mexico Motion Sickness Treatment Market by Distribution Channel
- 6.4 Rest of North America Motion Sickness Treatment Market
- 6.4.1 Rest of North America Motion Sickness Treatment Market by Drug Class
- 6.4.2 Rest of North America Motion Sickness Treatment Market by Route of Administration
- 6.4.3 Rest of North America Motion Sickness Treatment Market by Distribution Channel
- Chapter 7. Company Profiles
- 7.1 Viatris, Inc.
- 7.1.1 Company Overview
- 7.1.2 Financial Analysis
- 7.1.3 Segmental Analysis
- 7.1.4 Research & Development Expense
- 7.2 Teva Pharmaceutical Industries Ltd.
- 7.2.1 Company Overview
- 7.2.2 Financial Analysis
- 7.2.3 Regional Analysis
- 7.2.4 Research & Development Expenses
- 7.3 Amneal Pharmaceuticals, Inc.
- 7.3.1 Company Overview
- 7.3.2 Financial Analysis
- 7.3.3 Segmental Analysis
- 7.3.4 Research & Development Expenses
- 7.4 Baxter International, Inc.
- 7.4.1 Company Overview
- 7.4.2 Financial Analysis
- 7.4.3 Segmental Analysis
- 7.4.4 Research & Development Expense
- 7.5 Novartis AG
- 7.5.1 Company Overview
- 7.5.2 Financial Analysis
- 7.5.3 Segmental and Regional Analysis
- 7.5.4 Research & Development Expense
- 7.6 Abbott Laboratories
- 7.6.1 Company Overview
- 7.6.2 Financial Analysis
- 7.6.3 Segmental and Regional Analysis
- 7.6.4 Research & Development Expense
- 7.6.5 SWOT Analysis
- 7.7 Sun Pharmaceutical Industries Ltd.
- 7.7.1 Company Overview
- 7.7.2 Financial Analysis
- 7.7.3 Regional Analysis
- 7.7.4 Research & Development Expenses
- 7.8 Zydus Lifesciences Ltd.
- 7.8.1 Company Overview
- 7.8.2 Financial Analysis
- 7.8.3 Segmental and Regional Analysis
- 7.8.4 Research & Development Expense
- 7.8.5 Recent strategies and developments:
- 7.8.5.1 Trials and Approvals:
- 7.9 Prestige Consumer Healthcare, Inc.
- 7.9.1 Company Overview
- 7.9.2 Financial Analysis
- 7.9.3 Segmental and Regional Analysis
- 7.10. WellSpring Pharmaceutical Corporation (Avista Capital Partners)
- 7.10.1 Company Overview
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook